University of Sussex
Browse

File(s) not publicly available

Drug safety and the safety of patients: the challenge to medicine and health from permissive expert risk assessments of triazolam (Halcion)

journal contribution
posted on 2023-06-07, 21:59 authored by John Abraham
When assessing the risks and benefits of medical drugs, the approach may be precautionary or permissive. If these different approaches actually influence the analysis and interpretation of technical medical data, then they are not merely a matter for discussion among philosophers, but should be debated by those concerned about medical risks and public health. To examine the interaction between expert risk-benefit assessments of drugs, on the one hand, and permissive/precautionary approaches, on the other, the triazolam (Halcion) case is scrutinised. Specifically, the assessments of triazolam by the FDA's 1992 Psychopharmacological Drugs Advisory Committee (PDAC) and the National Academy of Sciences' 1997 Institute of Medicine (IoM) are analysed. Both the PDAC and the IoM exhibited permissiveness towards triazolam. The PDAC gave priority to anecdotal evidence about triazolam in use, when assessing efficacy, but to controlled clinical trial data, when assessing safety. In each instance the types of data which favoured triazolam were given priority. While a lack of compelling evidence of efficacy from clinical trials was regarded as insufficient to negate the drug's benefits, compelling evidence from clinical trials was required to confirm signals of lack of safety. The IoM and the PDAC avoided the problem of patient safety in 'the real world' by limiting their conclusions to the safety of the drug under the conditions of use recommended on the label. Whether or not a society adopts a precautionary or permissive approach to the risk assessments of new technologies is not merely a matter for technical experts and science, it is also a social and political matter. A precautionary approach to drug safety could yield different expert assessments. It might require compelling evidence of drug efficacy where good alternative therapies exist; integrate how a drug can be used safely into evaluation of controlled clinical trial data; and put more emphasis on the correlation between disaggregated clinical trial data and spontaneous reports of adverse drug reactions.

History

Publication status

  • Published

Journal

Health, Risk and Society

ISSN

13698575

Publisher

Taylor & Francis

Issue

1

Volume

4

Page range

19-29

Pages

11.0

Department affiliated with

  • Sociology and Criminology Publications

Full text available

  • No

Peer reviewed?

  • Yes

Legacy Posted Date

2012-02-06

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC